Factors modifying the migration of lymphocytes across the blood-brain barrier

International Immunopharmacology

Volumn 1, Issue 12, 2001, Pages 2043-2062

  Alun Brown, K ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Blood; Brain; Lymphocyte

Indexed keywords

ANTIBODY; BETA1 INTEGRIN; BETA2 INTEGRIN; BETA7 INTEGRIN; CD11 ANTIGEN ANTIBODY; CD18 ANTIGEN ANTIBODY; CD31 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; HERMES ANTIGEN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 1; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN; PADGEM PROTEIN; RANTES; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4 ANTIBODY; VERY LATE ACTIVATION ANTIGEN 6;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BLOOD BRAIN BARRIER; BLOOD VESSEL WALL; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DEMYELINATION; DISEASE COURSE; DISEASE EXACERBATION; ENDOTHELIUM CELL; HUMAN; LEUKOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NONHUMAN; PARENCHYMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ASTROCYTES; AUTOIMMUNE DISEASES; BLOOD-BRAIN BARRIER; BRAIN; CALLITHRIX; CELL ADHESION; CELL ADHESION MOLECULES; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX PROTEINS; FORECASTING; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; METALLOENDOPEPTIDASES; MICE; MICROCIRCULATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; RATS; T-LYMPHOCYTE SUBSETS;

EID: 0034773768     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00129-1     Document Type: Review

References (182)

1. Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity
2. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
3. Immunologically privileged sites
4. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: A new view
5. Nervous tissue as an immune compartment: The dialect of the immune response in the CNS
6. T-lymphocyte entry into the central nervous system
7. Inflammation in the nervous system. Basic mechanisms and immunological concepts
8. Immunopathogenesis of multiple sclerosis: The role of T cell
9. Progress in determining the causes and treatment of multiple sclerosis
10. The Dale E McFarlin memorial lecture: The immunology of the multiple sclerosis lesion
11. The role of B cells and autoantibodies in multiple sclerosis
12. Ubiquitous pathogens. Links between infection and autoimmunity in MS?
13. Autoimmune pathogenesis of multiple sclerosis: Role of autoreactive T lymphocytes and new immunotherapeutic strategies
14. Pathogenesis of tissue injury in MS lesions
15. Multiple sclerosis: A pivotal role for the T cell in lesion development
16. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system
17. Clinical trials of interferons in multiple sclerosis. What have we learned?
18. Analysis of effector (CD4 9OX-40+) and CD8 (CD45RA+CD27-) T lymphocytes in active multiple sclerosis
19. Increased numbers of mononuclear cells from blood and CSF expressing interferon-gamma mRNA in multiple sclerosis are from both the CD4+ and the CD8+ subsets
20. Colocolization of lymphocytes bearing gamma delta T-cell receptor heat shock protein hsp65+ oligodendrocytes in multiple sclerosis
21. Multiple sclerosis: Limited diversity of the V delta 2-J delta 3 T-cell receptor in chronic active lesions
22. T cell receptor gamma delta repertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: Molecular and functional analysis of antigen-reactive gamma delta clones
23. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors
24. Evidence for a role of γδ T cells in demyelinating diseases as determined by activation states and responses to lipid antigens
25. The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis
26. Chronic localization of myelin-reactive cells in the lesions of relapsing EAE: Implications for the study of multiple sclerosis
27. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: Effects of interferon β-1b therapy
28. Cell adhesion molecules: Selectins and integrins
29. Endothelial-leukocyte adhesion molecules
30. The biology of PECAM-1
31. The role of integrins in immune-mediated diseases of the nervous system
32. Chemokines and the arrest of lymphocytes rolling under flow conditions
33. CD44 and its interaction with the extracellular matrix
34. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: A novel lymphocyte-endothelial cell primary adhesion pathway
35. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extraversation
36. Lymphocyte recognition of high endothelium: Antibodies to distinct epitopes of an i5 kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells
37. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leucocytes
38. + T cells of both the naïve and the memory phenotype enter rat lymph nodes and Peyer's patches via high endothelial venules: Within tissue their migratory behaviour differs
39. Naïve and memory T lymphocytes migrate in comparable numbers through normal rat liver: Activated T cells accumulate in the periportal field
40. Relapsing autoimmune demyelination: A role for vascular addressins
41. Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies
42. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis
43. Distribution of immunoglobulin superfamily members, ICAM-1, -2, -3 and the β2 integrin LFA-1 in multiple sclerosis lesions
44. Endothelial cell expression of the intercellular adhesion molecule (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental allergic encephalomyelitis
45. Tumor necrosis factor identified in multiple sclerosis brain
46. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: Detection by non-radioactive in situ hybridization
47. Short-lived immunization site inflammation in self-limited active experimental allergic encephalomyelitis
48. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions
49. Adhesion molecules on endothelial cells in the central nervous system: An emerging area in the neuroimmunology of multiple sclerosis
50. Direct injection of cytokines into the spinal cord causes autoimmune encephalomyelitis-like inflammation
51. Lymphotoxin and tumor necrosis factor-α production by myelin basic protein-specific T cell clones correlates with encephalitogenicity
52. Human tumor necrosis factor-α augments experimental allergic encephalomyelitis in rats
53. An antibody to lymphotoxin and tumour necrosis factor prevents transfer of experimental allergic encephalomyelitis
54. EAE: Immunotherapy with anti-TNF antibodies and soluble TNF receptors
55. Mechanisms of inflammation in MS tissue: Adhesion molecules and chemokines
56. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1
57. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intracellular adhesion molecule ICAM-1
58. Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis
59. Augmentation of adoptively transferred EAE by administration of monoclonal antibodies specific for LFA-1 alpha
60. Controlling effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theilar's murine encephalomyelitis
61. E- and P-selectin are not involved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis
62. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse
63. Homing to central nervous system vasculature by antigen-specific lymphocytes: II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination
64. Regulated expression and binding of three VLA β(1) integrin receptors on T cells
65. Role of adhesion molecules in T-cell recognition. Fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-6) in expression, binding and co-stimulation
66. T cell memory: The connection between function, phenotype and migration pathway
67. Adhesion molecule expression on cerebrospinal fluid T lymphocytes: Evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis and normal controls
68. Migration of haematogenous cells through the blood-brain barrier and the initiation of CNS inflammation
69. Selective localisation of neuro-specific T lymphocytes in the central nervous system
70. Enhanced binding of lymphocytes from patients with multiple sclerosis to TNF-treated endothelial monolayers: Associations with clinical relapse and adhesion molecule expression
71. Lymphocyte-endothelial cell interactions in multiple sclerosis: Disease specificity and relationship to circulating tumour necrosis factor-α and soluble adhesion molecules
72. Selective binding of peripheral blood lymphocytes to the walls of cerebral vessels in frozen sections of human brain
73. Adhesion of mononuclear cells from multiple sclerosis patients to cerebral vessels in cryostat sections of normal human brain
74. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin
75. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma
76. Evidence for a prolonged role of α4 integrin throughout active experimental allergic encephalomyelitis
77. Therapy with antibody against leucocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis
78. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma
79. The development of experimental autoimmune encephalomyelitis in the mouse requires α4-integrin but not α4β7-integrin
80. Distinct roles for matrix metalloproteinase-2 and α4 integrin in autoimmune T cell extravasation and residency in brain parenchyma during experimental autoimmune encephalomyelitis
81. Adhesion molecule expression on cerebrospinal fluid T lymphocytes: Evidence for common recruitment mechanisms in multiple sclerosis, asceptic meningitis and normal controls
82. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia
83. The effect of anti-alpha 4 integrin antibody on brain lesion activity in MS
84. Distinction of virgin and memory T lymphocytes. Stable acquisition of the pgp-1 glycoprotein concomitant with antigen-stimulation
85. Phenotyping analysis of peripheral blood leukocytes in patients with multiple sclerosis
86. + T cells with a transendothelial migratory capacity
87. CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease
88. Antibodies to CD44 and integrin α4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment
89. Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis
90. Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1 α
91. Antibodies to CD44 and integrin alpha(4), but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment
92. Inhibition of experimental allergic encephalomyelitis with an antibody that recognizes a novel antigen expressed on lymphocytes, endothelial cells, and micoglia
93. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: An indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier
94. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis
95. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis
96. Longitudinal study of soluble adhesion molecules in multiple sclerosis: Correlation with gadolinium enhanced magnetic resonance imaging
97. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: Predominant intrathecal release of vascular cell adhesion molecule-1
98. Serum soluble adhesion molecules in multiple sclerosis: Raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease
99. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells
100. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular adhesion molecule-1
101. Lymphocyte interactions with endothelial cells
102. Regulation of the VLA integrin-ligand interactions through the (1 subunit)
103. Circulating L-selectin in multiple sclerosis patients with active, gadolinium-enhancing brain plaques
104. Soluble CD4 and CD8 in the peripheral blood of patients with multiple sclerosis and HTLV-1 associated myelopathy
105. Shedding of TNF receptors in multiple sclerosis patients
106. Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions
107. Transient increase in symptoms associated with cytokine release in patients with MS
108. Increased levels of circulating ICAM-1 in the serum and CSF of patients with active MS. Correlation with TNFα and blood-brain barrier damage
109. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
110. Cytokines and soluble IL-4 in patients with acute optic neuritis and multiple sclerosis
111. Antigen-specific T cell trafficking into the central nervous system
112. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T cell clones
113. Astocytes present myelin basic protein to encepholitogenic T-cell lines
114. Human brain microvascular DR-antigen
115. Antigen presentation and tumour cytotoxic by interferon-γ-treated microglial cells
116. Expression of Ia-like antigens by human vascular endothelial cells is inducible in vitro: Demonstration by monoclonal antibody binding and immunoprecipitation
117. Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naïve T cells
118. Interaction between myelin basic protein-sensitized T lymphocytes and murine cerebral vascular endothelial cells
119. Antigen presentation in brain: Brain endothelial cells are poor stimulators of T cell proliferation
120. B7 expression and antigen presentation by human brain endothelial cells: Requirement for proinflammatory cytokines
121. Characterization of inflammatory infiltrates in experimental allergic encephalomyelitis
122. On the immunopathology of plaque development and repair in multiple sclerosis
123. On the presence of Ia-positive endothelial cells and astrocytes in multiple sclerosis lesions and its relevance to antigen presentation
124. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis
125. Astrocytes and central nervous system endothelial cells do not express β7-1 (CD80) or β7-2 (CD86) immunoreactivity during experimental autoimmune encephalomyelitis
126. + T cells
127. Chemokines - Chemotactic cytokines that mediate inflammation
128. Perivascular T cells express the proinflammatory chemokine RANTES mRNA in multiple sclerosis lesions
129. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study
130. + T cells are increased in multiple sclerosis and their ligands MIP-1 α and IP-10 are expressed in demyelinating brain lesions
131. MIP-1 alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation
132. An important role for the chemokine macrophage inflammatory protein-K in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis
133. Identification of cell types producing RANTES, MIP-1 α and MIP-1 β in rat experimental autoimmune encephalomyelitis by in situ hybridization
134. Differential expression of chemokine and chemotactic responsiveness of type 1 helper cells (Th1s) and Th2s
135. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients
136. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s
137. Aberrant T cell migration toward RANTES and MIP-1 α in patients with multiple sclerosis: Over-expression of chemokine receptor CCR5
138. Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis
139. Central nervous system chemokine mRNA accumulation follows leucocyte entry at the onset of murine acute experimental autoimmune encephalomyelitis
140. A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination
141. The matrix degrading metalloproteinases
142. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system
143. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview
144. Processing of tumour necrosis factor-α precursor by metalloproteinases
145. Matrix metalloproteinases degrade myelin basic protein
146. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution
147. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis
148. Injury-induced 92-rkilodalton gelatinase and urokinase expression in rat brain
149. Matrix metalloproteinase expression in an experimentally induced DTH model of multiple sclerosis in the rat CNS
150. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders
151. Structural biochemistry and activation of matrix metalloproteases
152. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution
153. T cell gelatinases mediate basement membrane transmigration in vitro
154. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium
155. Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for multiple sclerosis
156. Antibody facilitation of multiple sclerosis-like lesions in a non human primate
157. Role of cytokines in rheumatoid arthritis
158. Anti-tumour necrosis factor-alpha therapy of rheumatoid arthritis
159. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumour necrosis factor antibody eA2
160. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
161. On cerebrospinal fluid immunoglobulin G (IgG) quotients in multiple sclerosis and other diseases
162. Treatment with BBB 022A or rolipram stabilises the blood-brain barrier in experimental autoimmune encephalomyelitis: An additional mechanism for the therapeutic effect of type IV phosphodisterase inhibitors
163. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury
164. Inteferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
165. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: A multicenter, randomized clinical trial
166. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II MRI analysis results of a multicenter, randomized, double blind, placebo-controlled trial
167. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer
168. Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy
169. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis
170. Interferon β-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
171. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1 α by interferon-β
172. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta
173. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b
174. Changes of serum sICAM-1 and MMP-9 induced by rIFN beta-1b treatment in relapsing-remitting MS
175. Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis
176. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis
177. Migratory behaviour of lymphocytes isolated from multiple sclerosis patients: Effects of interferon beta-1b therapy
178. Expression of the β-chemokines RANTES and MIP-1β by human brain microvessel endothelial cells in primary cultures
179. Local neurochemicals and site-specific immune regulation in the CNS
180. Intracerebral injection of pro-inflammatory cytokines or leucocyte chemotaxis induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system
181. Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis